These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 36232334)

  • 1. S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma.
    Delangre E; Oppliger E; Berkcan S; Gjorgjieva M; Correia de Sousa M; Foti M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Krizanac M; Mass Sanchez PB; Weiskirchen R; Asimakopoulos A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling.
    Teng F; Jiang J; Zhang J; Yuan Y; Li K; Zhou B; Zhou X; Liu W; Zhang P; Liu D; Zheng M; Lu Y; Zhang H
    Metabolism; 2021 Apr; 117():154725. PubMed ID: 33571540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
    Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
    J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
    Di Maira G; Foglia B; Napione L; Turato C; Maggiora M; Sutti S; Novo E; Alvaro M; Autelli R; Colombatto S; Bussolino F; Carucci P; Gaia S; Rosso C; Biasiolo A; Pontisso P; Bugianesi E; Albano E; Marra F; Parola M; Cannito S
    J Pathol; 2022 May; 257(1):82-95. PubMed ID: 35064579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
    Wang K; Wei Y; Xu R; Li Y; Mao C
    Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.
    Sobolewski C; Abegg D; Berthou F; Dolicka D; Calo N; Sempoux C; Fournier M; Maeder C; Ay AS; Clavien PA; Humar B; Dufour JF; Adibekian A; Foti M
    Gut; 2020 Oct; 69(10):1841-1854. PubMed ID: 31919231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
    Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights.
    Mass Sanchez PB; Krizanac M; Weiskirchen R; Asimakopoulos A
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.
    Masarone M; Troisi J; Aglitti A; Torre P; Colucci A; Dallio M; Federico A; Balsano C; Persico M
    Metabolomics; 2021 Jan; 17(2):12. PubMed ID: 33458794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover.
    Simon J; Ouro A; Ala-Ibanibo L; Presa N; Delgado TC; Martínez-Chantar ML
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
    Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
    Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100 family members: potential therapeutic target in patients with hepatocellular carcinoma: A STROBE study.
    Zhang C; Yao R; Chen J; Zou Q; Zeng L
    Medicine (Baltimore); 2021 Jan; 100(3):e24135. PubMed ID: 33546025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver endothelial cells in NAFLD and transition to NASH and HCC.
    Velliou RI; Legaki AI; Nikolakopoulou P; Vlachogiannis NI; Chatzigeorgiou A
    Cell Mol Life Sci; 2023 Oct; 80(11):314. PubMed ID: 37798474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of RECK in Hepatobiliary Neoplasia Reveals Its Therapeutic Potential in NASH.
    Dashek RJ; Diaz C; Chandrasekar B; Rector RS
    Front Endocrinol (Lausanne); 2021; 12():770740. PubMed ID: 34745017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.